Higher Body Mass Index Is Associated with Better Survival in Patients with Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) comprise a group of heterogeneous clonal hematopoietic stem cell disorders characterized by cytopenias(s), morphologic evidence of dysplasia in one or more hematopoietic cell lines, and ineffective hematopoiesis. Patients with MDS have a variable risk of progression to acute myeloid leukemia (AML). The pathophysiology of MDS is complex and involves abnormalities in the regulation of cellular proliferation, maturation, and interactions with the bone marrow microenvironment that result in heterogeneous outcomes.
Source: Leukemia Research - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research